The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration
Variations in the timing of sepsis treatment with TCZ yield significantly different molecular outcomes, histopathological results, and survival rates. A thorough investigation of the timing of immunotherapeutic applications in sepsis treatment will enhance the efficiency of sepsis treatments.
Authors
- Elif Çadırcı (ORCID: https://orcid.org/0000-0003-0836-7205)
- Kamber Kaşalı (ORCID: https://orcid.org/0000-0002-2851-5263)
- Taha Tavacı (ORCID: https://orcid.org/0000-0002-8284-8317)
- Mustafa Özkaraca (ORCID: https://orcid.org/0000-0002-6359-6249)
- Zekai Halıcı
Institutions
- Sakarya University (TR)
- Sivas Cumhuriyet Üniversitesi (TR)
- Atatürk University (TR)
Publication Details
- Journal
- Inflammopharmacology
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1007/s10787-025-01649-6
- Citations
- 5
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- Sakarya Üniversitesi
- Atatürk Üniversitesi